AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04411771 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief interventions
Description: 'Brief Interventions' (BI) is a generic term for a multitude of tools and interventions used in patient visits within PCBH. BI start immediately at the initial consultation, which ends with a personally tailored and evidence-informed plan adjusted to the patient's context. As such, there is no separation between assessment and intervention. The interventions within BI often have their foundation in CBT, ACT or MI. The common theme is that they are principle-based rather than manual-based and focus on behavioral change in relation to a problem that is perceived both possible to affect and relevant to the patient, rather than focusing on a specific diagnosis or condition. Follow-up appointments are scheduled flexibly depending on the patient's perceived need. Usually a BI treatment consists of 1-4 appointments with several weeks apart and ends when the patient feels that they are moving in the right direction.
Study NCT04411771 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Guided self-help CBT
Description: The patient receives a previously scientifically evaluated CBT-based self-help book for one of the following conditions: depression, generalized anxiety disorder, panic disorder, social anxiety, health anxiety, insomnia, or stress/burnout. The therapist support consists of 3-6 contacts throughout the 6-12 weeks long intervention period as decided by the clinician and patient together, as long as at least one and not more than three are physical visits at the center and the rest via phone, video conferencing, or secure internet messages. Clinicians delivering shCBT will need four days of reading and two days of training to be able to make initial assessments and problem profiling and use the self-help books.
Study NCT04347889 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Oral loading dose followed by once weekly dosing
Study NCT04347889 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin C
Description: Once daily vitamin C 1 gm
Study NCT03750643 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered IV
Study NCT01106235 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: therapeutic autologous lymphocytes
Description: Given IV
Study NCT01106235 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: aldesleukin
Description: Given SC
Study NCT01106235 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV
Study NCT01106235 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: biopsy
Description: Optional correlative studies
Study NCT01979133 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Icariin
Description: Participants will receive 20% icariin (100 mg/day) in a commercially available over-the-counter Horny Goat Weed supplement. A dose titration from 100 mg/day to 200 mg/day will be allowed at week 3 participants with less than a 30% reduction in HAMD and/or still using cocaine or alcohol or have a positive urine drug screen. An additional dose titration to 300 mg/day will be allowed at week 6 for participants with less than a 50% reduction in HAMD scores and/or still using cocaine or alcohol or have a positive urine drug screen.
Study NCT01303198 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: APAP - Therapy
Description: automatic positive pressure therapy
Study NCT00901121 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Straumann BoneCeramic
Description: Straumann BoneCeramic (500-1000 microns, 0.5g)
Study NCT00901121 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bio-Oss
Description: Bio-Oss spongiosa granules, size of particle 0.25-1 mm
Study NCT04043078 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Exercise
Description: The exercise regime will include daily upper limb aerobic (hand bike) and inspiratory muscle training (POWERbreathe) and upper body strength training every second day until discharge.
Study NCT00968877 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cholecalciferol
Description: capsule 40 000 IU (p.o.) once per week, in 8 weeks.
Study NCT00968877 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cholecalciferol
Description: capsule 40 000 IU (p.o.) once per week, in 8 weeks.
Study NCT00965419 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Edivoxetine
Description: 0.1 mg/kg/day or participant specific known stable dose, rollover participants (LNBJ \[No NCT number\]) and (LNBF \[NCT00922636\]), up to 0.3 mg/kg/day, oral, daily for up to 5 years.
Study NCT03322150 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atropine
Description: Atropine injection (0.01 mg/kg, max 0.5 mg) 3 minutes before spinal anesthesia
Study NCT03322150 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glycopyrrolate
Description: Glycopyrrolate (0.00 4mg/kg, max 0.2 mg) 3 minutes before spinal anesthesia
Study NCT05840536 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide plus Chlorothiazide
Description: Patients will receive lasix infusion starting at 5mg/hr along with a bolus dose of chlorothiazide 250mg at the initiation of the protocol. The lasix infusion can be titrated to 10mg after 12hrs based on volume of diuresis. This arm will also receive 250mg bolus doses of chlorothiazide every 12hrs for the duration of the study.~Intravenous (IV) lasix infusion at 5mg/hr plus IV boluses of diuril every 12 hrs.
Study NCT05840536 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide
Description: Patients will receive furosemide infusion at 5mg/hr along with an initial bolus dose of furosemide equal to twice their home oral dose. The furosemide infusion can be increased to 10mg/hr after 12hrs based on urine output. This arm will receive bolus doses of furosemide every 12hrs equal to twice their home oral dose until completion of the protocol.
Study NCT02146885 — intervention group
Intervention type: OTHER
Intervention: Weight Control
Description: Weight Control
Study NCT00334438 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: rituximab
Description: 250mg/m2, IV, Days 1 and 8
Study NCT00334438 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: bortezomib
Description: dose escalation 1.0, 1.3, or 1.5, IVP; Days 4, 8, 11, 15
Study NCT00334438 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: yttrium Y 90 ibritumomab tiuxetan
Description: Dose dependant upon platelet count (0.4mCi/kg) not to exceed 32mCi; Day 8
Study NCT00334438 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Indium 111 ibritumomab tiuxetan
Description: 5cmCi; IV day 1
Study NCT00787371 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PegIntron (peginterferon alfa-2b)
Description: PegIntron 0.25 mcg/kg subcutaneously (SC) once a week (QW) for 12 weeks
Study NCT00787371 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PegIntron (peginterferon alfa-2b)
Description: PegIntron 0.5 mcg/kg SC QW for 12 weeks
Study NCT00787371 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PegIntron (peginterferon alfa-2b)
Description: PegIntron 1.0 mcg/kg subcutaneously (SC) once a week (QW) for 12 weeks
Study NCT04099576 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: physiotherapy and education
Description: Hot-pack, ultrasound, trancutaneus nerve electrical stimulation (TENS) and home program exercises were applied or given to the individuals within the physiotherapy program. In addition to physiotherapy, therapeutic neuroscience education were applied to experimental group. One-to-one speech sessions focusing on pain neurophysiology were organized twice a week for three weeks. Each session lasted 40 minutes. The Therapeutic neuroscience education program included nociception, ion channel neurophysiology, central and peripheral sensitization, methods to help reduce sensitization, neuroplasticity, psychosocial factors involved in the transition from acute pain to chronic pain and behavioral, cognitive responses to pain.
Study NCT04099576 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physiotherapy alone
Description: Hot-pack, ultrasound, trancutaneus nerve electrical stimulation (TENS) and home program exercises were applied or given to the individuals within the physiotherapy program.
Study NCT02011789 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Citrus Limonoid Beverage
Description: The limonoid containing beverage will be 12-oz buffered, sterile, orange flavored, artificially sweetened, containing 60 mg vitamin C, 11 mg riboflavin and 250 mg limonin glucoside.
Study NCT02011789 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Citrus Limonoid Beverage
Description: The limonoid containing beverage will be 12-oz buffered, sterile, orange flavored, artificially sweetened, containing 60 mg vitamin C, 11 mg riboflavin and 250 mg limonin glucoside.
Study NCT02011789 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Placebo beverage
Description: The placebo beverage will be 12-oz buffered, sterile, orange flavored, artificially sweetened, containing 60 mg vitamin C and 11 mg riboflavin.
Study NCT02011789 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo beverage
Description: The placebo beverage will be 12-oz buffered, sterile, orange flavored, artificially sweetened, containing 60 mg vitamin C and 11 mg riboflavin.
Study NCT02228850 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alprostadil
Study NCT04413175 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: music therapy
Description: Patients in the music group were provided music therapy that was prepared by the Turkish Psychological Association. They listened to the music that has a calming and relaxing effect for 20 min before and during the procedure.~A portable MP3 player connected to double earphones was used in the present study. After patients took the lithotomy position for cystoscopy, their headphones were inserted and music began to be played. Music was played to the individuals for 20 minutes before and during the procedure. Headphones were removed immediately after the procedure was completed and the double earphones were cleaned with antiseptic solution after each application.
Study NCT02163850 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Direct Flow Medical
Description: Direct Flow Medical Transcatheter Aortic Valve Replacement System (TAVR)
Study NCT02163850 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Commercially Available
Description: Medtronic CoreValve Transcatheter Aortic Valve Replacement System (TAVR) or Edwards SAPIEN Transcatheter Aortic Valve Replacement System (TAVR)
Study NCT03595670 — intervention group
Intervention type: OTHER
Intervention: standardized questionnaires
Description: standardized questionnaires concerning the perception
Study NCT03595670 — intervention group
Intervention type: OTHER
Intervention: interview
Description: Semi-directive interviews will be conducted. The purpose of this approach is to question the meaning of the disease (beliefs, representations), the psycho-social management of the disease, its inscription in the socio-cultural condition of the patients.
Study NCT03075475 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Common Elements Treatment Approach
Description: The Common Elements Treatment Approach (CETA), is a trans-diagnostic psychotherapy that is based on common evidence-based treatments for depression, anxiety, trauma and stress related disorders. This treatment can be used to treat individuals with any of these mental health problems and with any combination of these problems. CETA expands upon traditional treatment approaches that are designed to focus on one specific disorder and has been proven through multiple rigorous trials to reduce the burden of multiple common mental health problems and improve functionality among men and women living in low resource settings. CETA can be provided to people in their own communities by trained and supervised lay providers, for example community health workers.
Study NCT03137732 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Rectus Sheath Catheter
Description: Insertion of rectus sheath catheter via either method
Study NCT02751606 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ferumoxtran-10
Description: ferumoxtran-10 will be administered intravenously one day prior to the MRI scan
Study NCT02751606 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 7 Tesla MRI
Description: Subjects undergo a 7 Tesla MRI scan
Study NCT02751606 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3 Tesla MRI
Description: Subjects undergo a 3 Tesla MRI scan
Study NCT00887601 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK3134
Description: Single dose 25 mg (5 x 5 mg) MK3134 capsules in one of the four treatment periods.
Study NCT00887601 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Placebo
Description: Placebo capsules only in one of the four treatment periods.
Study NCT00887601 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil
Description: Single dose 5 mg donepezil capsules in two of the four treatment periods.
Study NCT00887601 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK3134
Description: Single doses of 1 mg, 5 mg, or 25 mg MK3134 capsules in the assigned treatment periods
Study NCT03143855 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lorcaserin
Description: Lorcaserin will be administered at a dose of 10 mg twice daily for 5 days
Study NCT03143855 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered twice daily for for 5 days
Study NCT03755037 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clomid, Respatio and Ethinyl estradiol
Description: Drugs were received during the menstrual cycle.
Study NCT03755037 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Clomid, Respatio and Ethinyl estradiol
Description: Drugs were received during the menstrual cycle.
Study NCT00914056 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lactulose
Description: withdrawal of lactulose
Study NCT04021342 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Montmorency tart cherry concentrate
Description: Based on previous analysis done by our laboratory each 60 ml of Montmorency tart cherry concentrate contains approximately 73.5 mg of anthocyanins (cyanidin-3-glucoside equivalents) and 178.8 mg of total phenolics (mean gallic acid equivalents)
Study NCT04021342 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo beverage matched for calorie content and visual properties of the cherry concentrate
Study NCT00578006 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questioners
Description: The investigators will ask you to fill out a brief paper questionnaire periodically to tell us how you are feeling, and how satisfied you are with your care.
Study NCT00578006 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: STAR website
Description: You can report your symptoms every time you come to Sloan-Kettering for an appointment or chemotherapy.
Study NCT03428230 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 30 mg Paracetamol 3% (1 mL)
Description: Single administration by intrathecal injection just before spinal anaesthesia. The injection will be performed according to the hospital procedures. For the intrathecal injection of Paracetamol followed by the intrathecal injection of the anaesthetic, two needles will be used: one introducer needle, which will serve to introduce the second needle through the skin, plus one intrathecal Pencil point needle (27-G or 25-Gauge or Reganesth or Nizell needle) to which the first syringe containing Paracetamol will be attached first, followed by the second syringe with the anaesthetic. In this way only one intrathecal puncture will be performed. Lumbar puncture will be done according to the standard hospital procedures.
Study NCT03428230 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 60 mg Paracetamol 3% (2 mL)
Description: Single administration by intrathecal injection just before spinal anaesthesia. The injections will be performed according to the hospital procedures. For the intrathecal injection of Paracetamol followed by the intrathecal injection of the anaesthetic, two needles will be used: one introducer needle, which will serve to introduce the second needle through the skin, plus one intrathecal Pencil point needle (27-G or 25-Gauge or Reganesth or Nizell needle) to which the first syringe containing Paracetamol will be attached first, followed by the second syringe with the anaesthetic. In this way only one intrathecal puncture will be performed. Lumbar puncture will be done according to the standard hospital procedures.
Study NCT03428230 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 90 mg Paracetamol 3% (3 mL)
Description: Single administration by intrathecal injection just before spinal anaesthesia. The injections will be performed according to the hospital procedures. For the intrathecal injection of Paracetamol followed by the intrathecal injection of the anaesthetic, two needles will be used: one introducer needle, which will serve to introduce the second needle through the skin, plus one intrathecal Pencil point needle (27-G or 25-Gauge or Reganesth or Nizell needle) to which the first syringe containing Paracetamol will be attached first, followed by the second syringe with the anaesthetic. In this way only one intrathecal puncture will be performed. Lumbar puncture will be done according to the standard hospital procedures.
Study NCT04247256 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRI Protocol
Description: FOLFIRI standard treatment on day 5 to 7 (both days included) of a 14 day period. repeated bi-weekly
Study NCT04247256 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCO-101
Description: Investigational Medicinal Product, oral tablet administered on day 1 to 6 (both days included) of a 14 day period. repeated bi-weekly
Study NCT03428230 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo, 0.9% saline solution
Description: Single administration by intrathecal injection just before spinal anaesthesia. The injections will be performed according to the hospital procedures. For the intrathecal injection of Placebo followed by the intrathecal injection of the anaesthetic, two needles will be used: one introducer needle, which will serve to introduce the second needle through the skin, plus one intrathecal Pencil point needle (27-G or 25-Gauge or Reganesth or Nizell needle) to which the first syringe containing Placebo will be attached first, followed by the second syringe with the anaesthetic. In this way only one intrathecal puncture will be performed. Lumbar puncture will be done according to the standard hospital procedures.
Study NCT03428230 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NIMP: Chloroprocaine HCl 1% (10 mg/mL), solution for injection
Description: Immediately after intrathecal administration of the Paracetamol dose or Placebo, all patients will receive a single intrathecal dose of Chloroprocaine HCl 1% according to the Summary of Product Characteristics indications. Time interval between the 2 administrations should not exceed 2 min.
Study NCT03428230 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NIMP: Chloroprocaine HCl 1% (10 mg/mL), solution for injection
Description: Immediately after intrathecal administration of the Paracetamol dose or Placebo, all patients will receive a single intrathecal dose of Chloroprocaine HCl 1% according to the Summary of Product Characteristics indications. Time interval between the 2 administrations should not exceed 2 min.
Study NCT00636116 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Crotalinae (pit viper) equine immune F(ab)2
Description: Anavip with Anavip Maintenance Therapy
Study NCT00636116 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Crotalinae (pit viper) equine immune F(ab)2
Description: Anavip with Placebo Maintenance Therapy
Study NCT00636116 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Crotalidae Polyvalent Immune Fab, ovine
Description: CroFab with CroFab Maintenance Therapy
Study NCT02365311 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: transesophageal echocardiography(TEE)
Description: Transesophageal echocardiography examination will be performed TLV in supine and lateral position, 10, 20 and 30 min during OLV in left lateral decubitus position. By using the transesophageal echocardiography, we will evaluate the changes of pulmonary blood flow and cardiac function.
Study NCT04041648 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L606 (Liposomal Treprostinil) Inhalation Solution 51ug
Description: Single ascending dose
Study NCT04041648 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: L606 Inhalation System
Description: Single ascending dose
Study NCT04041648 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: L606 Inhalation System
Description: Single ascending dose
Study NCT04041648 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Solution
Description: Single ascending dose
Study NCT03600311 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Caloric Restriction
Description: Participants will consume 15 kcal/kg FFM/day.
Study NCT03600311 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Caloric Restriction
Description: Participants will consume 15 kcal/kg FFM/day.
Study NCT03600311 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Post-Exercise Protein
Description: Participants will ingest 30 g of protein following exercise.